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ABSTRACT 
The COVID-19 pandemic has had and continues to have major impacts on planned 
and ongoing clinical trials. Its effects on trial data create multiple potential statistical 
issues. The scale of impact is unprecedented, but when viewed individually, many of 
the issues are well defined and feasible to address. A number of strategies and 
recommendations are put forward to assess and address issues related to estimands, 
missing data, validity and modifications of statistical analysis methods, need for 
additional analyses, ability to meet objectives and overall trial interpretability. 
Keywords: COVID-19, pandemic, clinical trials, missing data, estimands, statistical 
strategy, supportive analyses 
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1. Introduction 
The COVID-19 outbreak emerging in China in December 2019 quickly became a global 
pandemic as declared by the World Health Organization in March 2020. As of today, still 
only a few months into the pandemic, the disease and public health control measures are 
having very substantial impact on clinical trials globally. Quarantines, site restrictions, 
  
travel restrictions affecting participants and site staff, COVID-19 infections of study 
participants, and interruptions to the supply chain for study medication have led to 
operational problems, including difficulties in adhering to study protocols. Trial sponsors 
have rapidly responded to this crisis, where the overriding primary concern has been to 
protect participant safety. Some trials have been halted or enrolment suspended in the 
interest of participant safety. For ongoing trials, sponsors have implemented a variety of 
mitigations to assure safety of participants and address operational issues. 
The downstream effects of protocol deviations and trial conduct modifications lead 
to varying degrees of impacts on clinical trial data. The impacts, described in more detail in 
later sections, raise important statistical issues for the trial. In the extreme, trial integrity, 
interpretability, or the ability of the trial to meet its objectives could be compromised. 
Intermediate to that, planned statistical analyses may need to be revised or supplemented to 
provide a thorough and appropriate interpretation of trial results. This paper offers a 
spectrum of recommendations to address the issues related to study objectives, inference, 
and statistical analyses. The major categories of impacts and mitigations are summarized in 
Figure 1. 
The issues we discuss here largely involve ongoing trials, started before but 
conducted during the pandemic for non-COVID-19 related therapies. Many of the issues 
and recommendations will also apply to new trials.  Regulatory agencies have rapidly 
published guidance for clinical trial sponsors to address COVID-19 issues (FDA 2020, 
EMA 2020a, 2020b). The current paper is influenced by and expands upon these important 
guidance documents.  
The paper is organized as follows. In Section 2 we describe overall trial impact 
assessment. Section 3 considers assessment of impacts on the trial through the estimand 
  
framework. Section 4 summarizes recommendations for revised and supplemental analyses 
that may be needed for the trial, including the likely mechanisms of missing data and the 
recommended statistical approaches to address missingness. Section 5 outlines additional 
considerations for trial-level impact. A summary of recommendations is given in Section 6. 
Figure 1. Key dimensions of assessment, mitigations and documentation to address the 
COVID-19 impact 
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2. Pandemic-related Factors, Impacts, and Risk Assessment 
Examples of pandemic-related impacts on trials that may lead to statistical issues are given 
in Table 1. Some of the impacts are directly caused by pandemic control measures or 
COVID-19 disease, while others result from operational modifications applied to address 
  
the direct impacts on trial conduct. The pandemic may have different effects on individual 
participants depending on when they enter a trial. The methods for summarizing pandemic 
effects on participants are discussed in Section 4.3.3. 
Table 1. COVID-19-related factors and examples of their potential impacts on clinical 
trials. 
Factor  Example of Impact/ Risk 
Quarantines, travel limitations, 
participant unable/unwilling to travel to 
site due to personal pandemic-related 
reasons, site closures or reduced 
availability of site staff 
 Missed or delayed visits and 
assessments 
 Inability to access study treatment 
 Loss to follow-up 
 Longer query response time 
 Different investigators / different 
measurement modalities 
 Delayed site monitoring 
 Delayed patient enrolment 
Interruptions to supply chain of 
experimental drug and/or other 
medications 
 Missed dosing of study drugs 
 Changes in non-COVID-19 
concomitant medications 
Alternative administration of drug  Increased risk of dosing errors  
 Lack of equivalence of methods of 
administration 
Alternative collection of specimens  Challenges in reconciliation and 
verification 
Alternative data collection  Lack of exchangeability of methods 
COVID-19 infection / treatment  Temporary / permanent interruption 
of study treatment and/or study 
participation  
 Potential effect on efficacy 
endpoints /estimands / safety  
 Interactions of COVID-19 
concomitant medications with study 
drugs 
 
For trials impacted by the pandemic, assessing the change of the benefit/risk for 
participants is the first step in the decision-making process (FDA 2020). All 
  
recommendations in this article presuppose that appropriate steps have been taken to assure 
participant safety. 
2.1. Overall Risk Assessment 
Sponsors are advised to perform a risk assessment based on aggregated and blinded data to 
evaluate the likelihood of a trial to deliver interpretable results. It must start as a forward-
looking assessment in anticipation of effects not yet seen but with some likelihood to occur. 
It should continue throughout the conduct of the study in light of the evolving situation and 
accumulating data, considering regional differences in the infection status and pandemic-
control measures. All measures need to be taken to minimize sources of operational and 
statistical bias, especially regarding principal measures of efficacy and safety. Key 
elements are: 
 Determine whether any trial modifications should be performed to protect 
participant safety and minimize risks to trial integrity; 
 Identify all study participants who are affected by COVID-19 and understand how 
they are affected (e.g., treatment interruption, study discontinuation, missed visits) 
and what is the impact on the trial;  
 Determine what additional information needs to be collected in the study database 
or in the form of input from study investigators in order to adequately monitor, 
document, and address pandemic-related issues (feasibility to obtain such 
information and its quality may vary and this needs to be considered as part of the 
risk factors); 
  
 Understand reasons for treatment or study discontinuation and the impact on 
planned estimands and intercurrent events;  
 Evaluate extent of missing data and specific reasons for missingness;  
 Assess changes in enrollment and in study population over time;  
 Evaluate the protocol-specified assumptions and the likelihood that the trial would 
be able to achieve its goals; 
 Ideally, verify the usability of data captured from alternative methods (e.g., virtual 
audio or video visits) before implementing them. Such data may add more 
variability or not be interpretable; 
 Determine any changes to planned analyses and analysis population definitions, or 
additional sensitivity analyses that need to be pre-specified prior to unblinding. 
   
Based on the risk evaluations above, many sponsors have developed standardized 
metrics of trial operational status, such as rates of missed visits, discontinuations from 
treatment and study, protocol deviations, adverse events (AEs), to reinforce a consistent 
approach to risk monitoring and assessment. Such metrics are useful to identify trials that 
are more acutely impacted and to monitor the overall state of a portfolio of trials.  
3. Implications and Mitigations for Estimands 
The ICH E9(R1) Addendum (ICH, 2019) defines the estimand framework for ensuring that 
all aspects of study design, conduct, analysis, and interpretation align with the study 
  
objectives. It also provides a rigorous basis to discuss potential pandemic-related 
disruptions and to put them in the context of study objectives and design elements. 
For an affected trial, the first major question is whether the primary objective, and 
therefore the primary estimand, should target the treatment effect without potentially 
confounding influences of COVID-19. We recommend that for most studies started before 
the pandemic, the original primary objective should be maintained as designed, implying a 
treatment effect that is not confounded by pandemic-related disruptions. (For new studies, 
this definition of treatment effect may also be reasonable, but depends on many aspects of 
the trial design.) This does not automatically imply a broad “hypothetical estimand” with 
the same hypothetical scenario for all possible pandemic-related intercurrent events (ICE). 
Confounding may need to be addressed in different ways for different types of ICEs 
depending on the study context. We discuss this in Section 3.1.  Some changes in the 
original estimand definitions may, therefore, be needed to account for the pandemic-related 
disruptions. Sponsors may also consider additional estimands for exploratory purposes to 
characterize the treatment effect in specific conditions or sub-populations that emerged 
during the COVID-19 pandemic. 
In studies where estimand(s) have been explicitly defined in the original protocol, 
sponsors should examine the effect of pandemic-related disruptions on estimand attributes 
and modify them as appropriate. The necessary revisions may vary under different risk 
mitigation scenarios, such as continuing study enrolment as planned versus temporarily 
suspending enrolment. For studies without explicitly defined estimands, this section may be 
useful to guide thinking about pandemic-related impacts on study objectives, conduct, 
inference, and statistical analyses. 
  
Below we review each attribute of the estimand definition and highlight important 
pandemic-related considerations. In keeping with the ICH E9(R1) guideline, we make a 
distinction between intercurrent events and missing data handling. Intercurrent events are 
discussed in this section as one of five attributes used to define an estimand. Missed 
assessments that would have been meaningful for a given estimand if collected, while the 
study treatment continues as planned, should not be considered as ICEs. Such situations 
lead to missing data and should be considered as part of the missing data strategies in the 
context of an estimator, albeit in alignment with the estimand (see Section 4.2).  
Our discussion is mainly geared towards considerations for the primary efficacy 
estimands, but similar logic can be applied to other study estimands. 
3.1. Handling of Intercurrent Events 
Strategies for handling non-pandemic related ICEs should remain unchanged. Here we 
discuss handling of pandemic-related ICEs only. The estimand framework allows for 
different strategies to be used for different types of ICEs and such estimands will likely be 
the most appropriate in the current context.  
ICEs should be considered pandemic-related if they occur as a result of pandemic-
related factors and are not attributed to other non-pandemic related reasons, e.g., treatment 
discontinuation due to lack of efficacy or a toxicity. Pandemic-related ICEs of importance 
should first be categorized in terms of their impact on study treatment adherence (e.g., 
study treatment discontinuation) or ability to ascertain the target outcomes (e.g., death). 
These ICEs should then be further categorized according to pandemic-related factors in 
order to choose the appropriate strategies to handle them. The relevant factors are study 
treatment accessibility, participant’s COVID-19 infection condition, and participant’s 
  
concomitant treatment for COVID-19 in case of infection. The key attributes that, when 
taken together, describe each pandemic-related ICE are summarized in Table 2. For 
example, premature study treatment discontinuation (listed in row 1 of Table 2) would only 
be considered pandemic-related if it is caused by one or more pandemic-related factors 
(listed in rows 2-4 of Table 2) and not attributed to other factors such as lack of efficacy or 
study treatment toxicity.  (The list is not exhaustive and additional categories may need to 
be considered in some studies.) The combination of factors and therefore distinct varieties 
of ICEs is potentially large, but it may be decided that all or most ICEs can be handled in a 
similar manner. 
Table 2. Attributes of pandemic-related intercurrent events. 
Participant’s 
Adherence to Study 
Treatment  
 Study treatment permanently discontinued, and no new 
treatment started for disease under study; 
 Study treatment permanently discontinued and switched 
to an alternative therapy for disease under study;  
 Study treatment temporarily interrupted, or compliance 
significantly reduced without changes in concomitant 
therapy for disease under study; 
 Study treatment temporarily interrupted, or compliance 
significantly reduced with changes in the concomitant 
therapy for disease under study, e.g., start of rescue 
medications. 
Study Treatment 
Accessibility 
 Study/region-wise drug supply interruption; 
 Site unavailable to administer/dispense study treatment; 
 Study treatment available at site but participant is 
unable/unwilling to get study treatment due to personal 
pandemic-related reasons. 
Participant’s COVID-
19 Infection 
Condition 
 Participant positive for COVID-19 and alive; 
 Participant deceased due to COVID-19*; 
 Participant with a suspected COVID-19 infection (may be 
distinguished further by presence or absence of 
symptoms). 
 Participant with an exacerbation of underlying health 
issues due to reduced healthcare access. 
  
Participant’s COVID-
19 Concomitant 
Treatment(s) * 
 Participants treated for COVID-19 (pharmacologically, 
oxygen, etc.); 
 Hospitalized, not in intensive care; 
 Admitted to intensive care. 
* COVID-19 related deaths and initiation of treatment for COVID-19 infections 
may also be considered as ICEs if they occur after the completion of study 
treatment or after other non-pandemic-related ICEs and before the time point 
associated with the endpoint of interest. 
 
Certain types of non-adherence to study treatment may not normally be considered 
as ICEs but may need to be in the context of the pandemic. For example, an ICE of 
significantly reduced compliance or temporary treatment interruption may not have been 
anticipated at study design but could be now if considered likely due to pandemic-related 
disruptions. For some studies with significant pandemic-related treatment interruptions, the 
minimal duration of interruption expected to dilute the treatment effect could be defined. 
Different strategies can be used for interruptions exceeding this duration as opposed to 
shorter interruptions. Sensitivity analyses can be used to assess robustness of inference to 
the choice of cut-off. For time-to-event endpoints, it is tempting to define the minimally 
acceptable level of drug compliance on a participant level according to the observed 
exposure to study drug from the first dose of study drug until the event or censoring and 
exclude participants without a minimally acceptable level of compliance. However, such an 
approach could introduce immortal time bias and should therefore be avoided (van 
Walraven et al, 2004). 
A special consideration may be warranted for participants receiving experimental 
treatment for COVID-19 regardless of whether they remain on study treatment. Also, in 
studies where mortality was not originally expected, death due to COVID-19 should be 
considered as a potential ICE. 
  
Most of the ICE types listed against the “Participant’s Adherence to Study 
Treatment” attribute in Table 2 (e.g., study treatment discontinuation) due to non-pandemic 
related reasons are likely addressed in the primary estimand prior to the pandemic. We 
recommend starting with an examination of whether the original strategy is justifiable when 
these ICEs occur due to the pandemic. If not, a different strategy should be chosen. We 
outline some high-level considerations in this respect. 
 Treatment policy strategy, in which ICEs are considered irrelevant in defining the 
treatment effect, will typically not be of scientific interest for most pandemic-related 
ICEs because the conclusions would not generalize in the absence of the pandemic. 
For example, the treatment effect estimated under the treatment policy for 
premature treatment discontinuations caused by pandemic-related disruptions will 
reflect the effect of a regimen where discontinuations and changes in therapy occur 
due to pandemic-related factors (e.g., disruptions in study drug supply) which 
would not be aligned with the primary study objective. Initiation of treatment for 
COVID-19 infection after an earlier non-pandemic-related ICE that was planned to 
be handled by the treatment policy strategy but prior to observation of an efficacy or 
safety endpoint will also need to be considered carefully and cannot simply be 
deemed irrelevant. Under the treatment policy strategy, the estimated treatment 
effect may reflect the effects of infection and its treatment, which are presumably 
not of interest for the primary objective. 
A decision to use a treatment policy approach for pandemic-related ICEs may be 
justifiable if the percentage of participants with such events is low and this strategy 
was planned for similar non-pandemic related ICEs. This strategy may also be 
  
considered for handling ICEs corresponding to relatively short treatment 
interruptions. The treatment policy strategy should be avoided for pandemic-related 
ICEs of premature study treatment discontinuation in non-inferiority and 
equivalence studies, as similarity between treatment groups may artificially increase 
with the number of such events. Similar considerations also apply to the composite 
strategy. 
 Composite strategies, in which ICEs are incorporated into the definition of the 
outcome variable, are unlikely to be appropriate for most pandemic-related ICEs. 
For example, study treatment discontinuation due to pandemic-related disruptions 
should not be counted as treatment failure in the same way as discontinuation due to 
lack of efficacy or adverse reactions. A more nuanced consideration may be needed 
in studies of respiratory conditions, where COVID-19 complications may be 
considered with a composite strategy as a form of unfavourable outcome. (See also 
a discussion on COVID-19 related deaths further below.) 
 Principal stratification strategy stratifying on a COVID-19 related event (e.g., 
serious complications or death due to COVID-19) is unlikely to be of interest for 
the primary estimand because it would limit conclusions to a sub-population of 
participants defined based on factors not relevant in the context of the future clinical 
practice.  
 While-on-treatment strategy may continue to be appropriate under certain 
conditions if it was originally planned for non-pandemic-related ICEs. This strategy 
is typically justifiable when treatment duration is not relevant for establishing 
treatment effect (e.g., treatment of pain in palliative care), but certain conditions 
  
may need to be considered, such as a minimum treatment duration required to 
reliably measure treatment outcomes. 
 Hypothetical strategy, in which the interest is in the treatment effect if the ICE did 
not occur, is a natural choice for most pandemic-related ICEs. This would especially 
apply to ICEs of study treatment disruption for pandemic reasons. For such 
participants, the hypothetical scenario where they would continue in the study in the 
same way as similar participants with an undisrupted access to treatment is 
reasonable. It is not necessary to assume a hypothetical scenario where such 
participants would fully adhere to the study treatment through the end of the study. 
Rather, a hypothetical scenario may include a mixture of cases who adhere to the 
study treatment and those who don’t adhere for non-pandemic reasons. Discussions 
with regulatory agencies may be helpful to reach an agreement on the details prior 
to the final study unblinding. 
Although estimation methods are not part of the estimand consideration, the ability 
to estimate treatment effects in a robust manner under a hypothetical strategy based 
on available data should not be taken for granted and should be assessed as the 
estimand definition is finalized. This aspect should be part of the overall risk 
assessment and decisions on the choice of the mitigation strategies.  
The discussion above highlights the need to capture the information associated with 
pandemic-related factors, such as those listed in Table 2. This can be done either through 
designated fields in the Case Report Form (CRF) or through a detailed and structured 
capture of protocol deviations.  
An ICE of death due to COVID-19 requires careful consideration and the 
appropriate strategy depends on the disease under study and clinical endpoint. In disease 
  
areas with minimal mortality where death is not a component of the endpoint, a 
hypothetical strategy for deaths related to COVID-19 infections may be recommended. For 
studies in more severe diseases where death is part of the endpoint, it is inevitable that more 
than one estimand will be of interest when evaluating the benefit of treatment for regulatory 
purposes. A pragmatic approach which includes COVID-19-related deaths in the outcome, 
i.e., which uses a composite strategy, is suitable if the number of COVID-19-related deaths 
is low or if there is a desire to reflect the impact of the pandemic in the treatment effect 
estimate.  (See also the related section on competing risks analyses in Section 4.2.2.) Using 
a hypothetical strategy for deaths related to COVID-19 infections will be important in 
evaluating the benefit of treatment in the absence of COVID-19 (for example, when the 
disease is eradicated or effective treatment options emerge). It is acknowledged that such 
trials frequently include elderly, frail, or immunocompromised participants and it may be 
difficult to adjudicate a death as caused by COVID-19 or whether the participant died with 
COVID-19.   
While treatment policy, composite, and principal stratification strategies may not be 
of interest for the primary estimand, they may be of interest for supplementary estimands 
when there is a scientific rationale to investigate the study treatment either in sub-
populations of participants stratified based on COVID-19 infection and outcomes and/or 
together with a concomitant use of treatments administered for COVID-19. For example, 
this may be of interest for studies in respiratory diseases or conditions suspected to be risk 
factors for COVID-19 complications. The relevance of such estimands will also depend on 
the evolution of this pandemic, whether the virus is eventually eradicated or persists like 
seasonal flu. In the latter case, the reality and clinical practice are still likely to be different 
  
from the current crisis management conditions as the society and clinical practice adapt to 
deal with a new disease. 
3.2. Treatment Condition (Intervention) of Interest 
In general, treatment condition of interest should remain the same as originally intended. 
However, operationally, the mode of treatment delivery may need to be changed due to 
pandemic-related reasons, e.g., treatment self-administered by the participant at home 
rather than in the clinic by a health-care professional. When such changes are feasible, they 
may be considered to reduce the frequency of visits to the clinic, and therefore reduce the 
risk of infection exposure. 
Pandemic-related complications with study treatment adherence and concomitant 
medications should be considered as ICEs and handled with an appropriate strategy. The 
extent of such ICEs should be evaluated in terms of whether the treatment(s) received by 
participants during the study remain sufficiently representative of what was intended. This 
may include treatment interruptions, reduced compliance, and access to any background, 
rescue, and subsequent therapies planned to be covered by the treatment policy strategy.  
3.3. Target Population 
To align with the primary study objective, the target participant population should remain 
as originally planned, i.e., should not be altered simply due to the pandemic. Protocol 
amendments unrelated to the pandemic to further qualify the study population should still 
be possible. The trial inclusion/exclusion criteria should also remain largely unchanged 
relative to those that would be in place in absence of the pandemic, except for 
the possible exclusion of active COVID-19 infections. 
  
3.4. Variable (Endpoint) 
The clinical endpoint should generally remain as originally planned. In cases where 
alternative measurement modalities may be necessary during the pandemic, for example, 
central labs vs. local labs, remote assessments of questionnaires instead of in-clinic, etc., it 
must be assured that clinical endpoint measurement is not compromised and potential 
effects on endpoint variability should be assessed (see Section 4.3.2). In cases where 
pandemic-related ICEs, such as COVID-19 deaths, are handled using the composite 
strategy, the definition of the endpoint may need to be adjusted. In cases of numerous 
delays between randomization and start of treatment, where the endpoint is defined relative 
to the date of randomization (e.g., in time-to-event endpoints), consideration may be given 
to redefine the endpoint start date to start of treatment. However, in the context of open-
label studies this may not be advisable. 
3.5. Population-level Summary of Treatment Effect 
Population-level summary describing outcomes for each treatment and comparison between 
treatments should remain unchanged, in general. In rare situations, a summary measure 
may need to be changed, for example, if the originally planned endpoint is numeric and a 
composite strategy is used for COVID-19 deaths to rank them worse than any value in 
survived participants. In this case, a summary measure may be changed from mean to 
median. 
Another example could be a hazard ratio (HR) from a Cox proportional hazard 
regression, a summary measure of treatment effect commonly used for trials with time-to-
event endpoints. If the assumption of proportional hazards is not satisfied, the estimated HR 
depends on the specific censoring pattern observed in the trial, which is influenced both by 
  
participant accrual and dropout patterns (Rufibach, 2019). External validity and 
interpretability of the HR needs to be carefully considered if censoring patterns are affected 
during the pandemic in ways that are not representative of non-pandemic conditions and if 
additional pandemic-related censoring depending on covariates such as the participant’s age 
or comorbidities are observed. Similarly, the validity of the Log-rank test relies on the 
assumptions that the survival probabilities are the same for participants recruited early and 
late in the trial and that the events happened at recorded times. Such assumptions may need 
to be assessed. Supportive estimands with alternative summary measures could be 
considered (see e.g., Boyd et al., 2012; Nguyen and Gillen, 2012; Mao et al., 2018).  
4. Implications and Mitigations for Analysis 
Planned statistical analyses may need to be modified due to effects of the pandemic on 
trials. Additional sensitivity and supplementary analyses may be needed to properly 
understand and characterize the treatment effect. Depending on the trial, modifications in 
planned analyses may range from relatively minor, e.g., for trials with relatively low 
impact, to major, e.g. in settings where study drug administration and visits are severely 
disrupted by the pandemic. A general summary of analysis considerations is provided in 
Table 3 and detailed discussions are presented in subsequent sections. 
All planned modifications and additional analyses should be documented in the 
SAP prior to data unblinding and in the clinical study report. Additional post hoc 
exploratory analyses may also be necessary after study unblinding to fully document the 
impact of the pandemic and characterize the treatment effect in this context.   
  
Table 3: Summary of analysis considerations  
Review of planned 
analyses  
 Review all planned main and sensitivity analyses to ensure 
alignment with the revised estimand(s). 
 Review / amend methods for handling of missing data, or 
censoring rules, to accommodate pandemic-related 
missingness. 
Summaries of 
pandemic impact 
 Summarize the occurrence of pandemic-related ICEs and 
protocol deviations. 
 Summarize the number of missed or unusable assessments 
for all key endpoints. 
 Summarize the number of assessments performed using 
alternative modalities. 
 Summarize study population characteristics before and after 
pandemic onset. 
Additional 
sensitivity and 
supportive analyses 
 Plan additional analyses for sensitivity to pandemic-related 
missingness. 
 Consider the need for additional, alternative summary 
measures of treatment effect. 
 Consider exploring inclusion of additional auxiliary 
variables, interaction effects, and time-varying exogenous 
covariates in the analysis methods.  
 Consider subgroup analyses based on subgroups defined by 
pandemic impact, e.g. primary endpoint visits before or 
after pandemic onset.  
 Consider the need for evaluation of potential impact of 
alternative data collection modalities. 
 Consider sources of data external to the trial, for example to 
justify use of alternative modalities.   
 Plan for additional safety analyses. 
 
4.1. Considerations for Efficacy Analyses  
All planned efficacy analyses should be re-assessed considering the guidance provided in 
Sections 3 and in terms of handling of pandemic-related missing data (see Section 4.2). The 
core analysis methodology should not change. However, depending on the revisions to the 
estimand, the strategies chosen for pandemic-related ICEs, and the handling of pandemic-
related missing data, some changes to the planned analyses may be warranted. Additional 
analyses will frequently also be required to assess the impact of the pandemic disruption. 
  
Special considerations may be needed for studies and endpoints where participant outcomes 
could be directly impacted by the pandemic, e.g., in respiratory diseases or quality of life 
endpoints. 
In studies where enrolment is halted due to the pandemic, sponsors should compare 
the populations enrolled before and after the halt. More generally, shifts in the population 
of enrolled participants over the course of the pandemic should be evaluated. Baseline 
characteristics (including demographic, baseline disease characteristics, and relevant 
medical history) could be summarized by enrolment period to assess whether there are any 
relevant differences in the enrolled population relative to the pandemic time periods. Shifts 
could be associated with regional differences in rates of enrollment because start and stop 
of enrollment is likely to vary by country as pandemic measures are implemented or lifted.   
4.2. Implications and Mitigations for Missing Data 
Sponsors should make every effort to minimize the amount of missing data without 
compromising safety of participants and study personnel during the COVID-19 pandemic 
and placing undue burden on the healthcare system. Whenever feasible and safe for 
participants and sites, participants should be retained in the trial and assessments continued, 
with priority for the primary efficacy endpoint and safety endpoints, followed by the key 
secondary endpoints. Despite best efforts, sponsors should prepare for the possibility of 
increased amounts and/or distinct patterns of missing data.  
In the framework of ICH E9(R1), an assessment or endpoint value is considered 
missing if it was planned to be collected and considered useful for a specific estimand but 
ended up being unavailable for analysis. In case of ICEs that are addressed by a 
hypothetical strategy, endpoint values are not directly observable under the hypothetical 
  
scenario.  Such data are not missing in the sense of the ICH E9(R1) definition, however, 
they need to be modelled in the analysis, often using methods similar to those for handling 
of missing data. In the remainder of the paper, we will discuss methods for handling of 
missing data, and note that such methods can be useful for modelling unobserved data after 
ICEs, if the modelling assumptions align with the hypothetical scenarios chosen for 
addressing the corresponding ICEs.  
4.2.1. Assessing and Documenting Pandemic-related Missingness 
Sponsors should assess and summarize patterns (amount and reasons) of pandemic-related 
missing data in affected trials. Data may be missing because a) planned assessments could 
not be performed; b) collected data is deemed unusable for analysis, e.g., out-of-window; or 
c) data under a desired hypothetical scenario cannot be observed after an ICE (e.g., 
censored). Additionally, each pandemic-related missingness instance also has specific 
reasons and circumstances. At a high level, reasons for pandemic-related missing data 
could be structural (e.g., government enforced closures or sites stopping study-related 
activities) or they could be participant-specific (e.g., individual COVID-19 disease and 
complications or individual concerns for COVID-19). Table 4 outlines the aspects that 
together provide a comprehensive picture for assessing the impact of missing data and 
planning how to handle them in analysis. Sponsors should, therefore, capture such 
information in the clinical study database as much as possible. The last two rows of Table 4 
reflect circumstances similar to those that are considered in the context of ICEs (see Table 
2). Since missing data may occur both in the presence of ICEs (e.g., handled by a 
hypothetical strategy) and in the absence of ICEs (e.g., participant continues to adhere to 
study treatment but misses some assessments), we list them here as well.  
  
Table 4. Attributes of pandemic-related missing data. Row 1 summarizes reasons of 
missing data, rows 2-4 summarize related conditions that contribute to those reasons. 
Missing Endpoint 
Measurement 
 Assessment missing due to a participant’s premature 
discontinuation from the study overall for pandemic-
related reasons;  
 Assessment missing due to missed study visits/procedures 
while a participant remains in the study (intermittent 
missing data);  
 Assessment delayed (out-of-window) and deemed 
unusable for an analysis; 
 A composite score (e.g., ACR20 in rheumatoid arthritis) 
cannot be calculated because some components are 
missing; 
 Assessment deemed to be influenced by pandemic-related 
factors and deemed unusable for a particular analysis 
because the interpretability of the results may be 
impacted (e.g., in assessments of quality of life, 
activity/functional scales, healthcare utilization, etc);  
 Recorded data cannot be properly verified or adjudicated 
due to COVID-19-related factors and deemed to be 
unreliable for analysis; 
 Assessment performed after an intercurrent event 
intended to be handled with a hypothetical strategy and 
collected data are deemed unusable for this estimand. 
Assessment 
Accessibility 
 Site (facilities or staff) unavailable to perform study-
related assessments; 
 Site/assessment procedure available but participant is 
unable/unwilling to get assessment done due to personal 
pandemic-related reasons. 
Participant’s COVID-
19 Infection 
Condition 
 Participant positive for COVID-19 and alive; 
 Participant deceased due to COVID-19; 
 Participant without a known COVID-19 infection. 
Participant’s COVID-
19 Concomitant 
Treatment(s) 
 Participants treated for COVID-19 (pharmacologically, 
oxygen, etc.); 
 Hospitalized, not in intensive care; 
 Admitted to intensive care. 
 
Sponsors should also consider a potential for under-reporting of symptoms and AEs 
during the pandemic due to missed study visits or altered assessment modalities, e.g., a 
telephone follow-up instead of physical exam. (See Section 4.4.)   
  
Sponsors should also consider reporting patterns of missingness along several 
dimensions: over time (in terms of study visits as well as periods before and after the start 
of pandemic disruptions), with respect to certain demographic and baseline disease 
characteristics, as well as co-morbidities considered to be potential risk factors associated 
with COVID-19 infection or outcomes, and across geographic regions. 
Blinded summaries of missing data patterns prior to study unblinding may inform 
the choice of missing data handling strategies. It may be useful to compare missing data 
patterns from the current studies with similar historical studies, especially with respect to 
missingness in subgroups. 
After study unblinding (for final or unblinded DMC analyses), missing data patterns 
should be summarized overall and by treatment arm. Although in most cases pandemic-
related missingness, especially structural missingness, would not be expected to differ 
between treatment arms, such a possibility should not be ruled out. In special 
circumstances, such as in an open-label study, missing visits may be related to treatment if 
the experimental treatment must be administrated at the site while the control treatment 
could be administrated at home, there may be more missing assessments in the control 
group. This may result in biased treatment effect estimates if mitigating strategies are not 
implemented. This could also be the case for a single cohort trial using an external control. 
4.2.2. Handling of Missing Data in Main Analyses 
Sponsors should generally maintain the same approaches for handling of non-pandemic-
related missing data as originally planned in the protocol and SAP.  For pandemic-related 
missingness, appropriate strategies will need to be identified in the context of each 
estimand and analysis method. Which strategy is most appropriate should be considered in 
  
light of the underlying context and reasons for missingness as shown in Table 4 and in 
alignment with the estimand for which the analysis is performed.  Three cases are 
described.  
(1) When data are missing without the participant having an ICE, i.e., participant continues 
to adhere to study treatment but has some endpoint values missing: the missing data 
modelling should be based on clinically plausible assumptions of what the missing values 
could have been given the fact the participant continues to adhere to study treatment and 
the participant’s observed data.  
(2) When data are modelled in presence of an ICE: the strategy defined in the estimand for 
addressing that ICE should be considered.  
(3) When modelling outcomes after an ICE addressed by a hypothetical strategy: the 
assumptions should reflect what the unobserved outcome could have been under the 
specific hypothetical scenario specified in the estimand and be clinically plausible in the 
context surrounding the ICE. For example, unobserved data can be modelled differently for 
ICEs of study treatment discontinuation depending on whether the participants suffer from 
COVID-19 infection complications or not, as having such complications may indicate a 
different overall health state.   
Imputation methods or methods which implicitly deal with missing values 
recommended in the current literature and by regulatory agencies should, in most cases, 
provide an adequate selection of tools to deal with pandemic-related missingness (see e.g., 
Molenberghs and Kenward, 2007; NRC, 2010; O’Kelly and Ratitch, 2014, Mallinckrodt et 
al., 2019).  
Methods for dealing with missing data are often categorized based on the type of 
assumptions that can be made with respect to the missingness mechanism. Using 
  
Molenberghs and Kenward (2007)’s classification of missingness mechanisms aligned with 
longitudinal trials with missing data, data are missing completely at random (MCAR) if the 
probability of missingness is independent of all participant-related factors or, conditional 
upon appropriate pre-randomization covariates, the probability of missingness does not 
depend on either the observed or unobserved outcomes. (We note that in the framework of 
Little and Rubin (2002), MCAR is defined as independent of any observed or unobserved 
factors. This definition was subsequently generalized to encompass dependence on pre-
randomization covariates, also referred to as covariate-dependent missingness, and MCAR 
is now used in the literature in both cases.) Some types of pandemic-related missingness 
may be considered MCAR, e.g., if it is due to a site suspending all activities related to 
clinical trials. Consideration may be given to whether such participants should be excluded 
from the primary analysis set depending on the amount of data collected prior to or after the 
pandemic. For example, when all (most) data are missing for some participants, imputing 
their data based on a model from participants with available data would not add any new 
information to the inference, while excluding such participants is unlikely to introduce bias. 
When participants have data only for early visits before the expected treatment effect onset 
and the rest of the data are MCAR, then including such participants in the analysis set may 
not add information for inference about treatment effect while adding uncertainty due to 
missing data.  
Data are MAR if, conditional upon appropriate (pre-randomization) covariates and 
observed outcomes (e.g., before participant discontinued from the study), the probability of 
missingness does not depend on unobserved outcomes. If relevant site-specific and 
participant-specific information related to missingness is collected during the study, most of 
the pandemic-related missingness can be considered MCAR or MAR. 
  
 The definitions of MCAR and MAR mechanisms are based on conditional 
independence of missing data given a set of covariates and observed outcomes that explain 
missingness. The factors explaining pandemic-related missingness may include additional 
covariates and, in the case of MAR, post-randomization outcomes. For example, 
missingness during the pandemic may depend on additional baseline characteristics, e.g., 
age and co-morbidities, as well as post-randomization pandemic-related outcomes, such as 
COVID-19 infection complications.  
In the case of covariate-dependent missingness, regression adjustment for the 
appropriate baseline covariates is sufficient for correct inference, though this complicates 
the analysis model and the interpretation of the treatment effect for models such as logistic 
or Cox regression where conditional and marginal treatment effect estimates do not agree. 
Under MCAR and MAR, some modelling frameworks such as direct likelihood, e.g., mixed 
models for repeated measures (MMRM), can take advantage of separability between 
parameter spaces of the distribution of the outcome and that of missingness. In this case, 
missingness can be considered ignorable (Molenberghs and Kenward, 2007), and the 
factors related only to missingness do not need to be included in the inference about 
marginal effects of treatment on outcome. This does not, however, apply to all inferential 
frameworks. Multiple imputation (MI) methodology (Rubin, 1987) may be helpful in this 
respect as it allows inclusion of auxiliary variables (both pre- and post-randomization) in 
the imputation model while utilizing the previously planned analysis model. Multiple 
imputation with auxiliary variables may be used for various types of endpoints, including 
continuous, binary, count, and time-to-event and coupled with various inferential methods 
in the analysis step. The use of MI with Rubin’s rule for combining inferences from 
  
multiple imputed datasets may introduce some inefficiencies and impact study power, 
although some alternatives exist (see, e.g., Schomaker and Heumann, 2018; Hughes et al., 
2016).  
For implementing a hypothetical strategy for COVID-19 related ICEs in the context 
of time-to-event endpoints, regression models (e.g., Cox regression) adjusted for relevant 
baseline covariates (in the MCAR setting) or multiple imputation (in the MAR setting) is 
recommended. Competing risks analyses which treat pandemic-related ICEs that fully or 
partially censor the outcome, e.g., COVID-19 related deaths, as competing events are not 
compatible with a hypothetical strategy. A further complication in the interpretation of 
competing risks analyses in this context is that participants are not at risk for the competing 
event from their time origin (e.g., randomization or start of treatment) onwards but only 
during the pandemic which is not experienced synchronously across the trial cohort. This 
compromises the validity of common competing risks analyses and prevents interpretation 
of results from such analyses to be generalized to the population. 
The implication of assuming specific missingness mechanism is that missing 
outcomes can be modelled using observed pre-randomization covariates or covariates and 
post-randomization outcomes (MAR) from other “similar” participants, conditional on the 
observed data. For pandemic-related missingness, it is important to evaluate whether there 
are sufficient observed data from “similar” participants to perform such modelling, even if 
factors leading to missingness are known and collected. For example, if missingness and 
endpoint depend on age, and few older participants have available endpoint data, it may not 
be appropriate to model missing data of older participants using a model obtained primarily 
from available data of younger participants (possibly resulting in unreliable extrapolation). 
  
Similarly, severe complications of a COVID-19 infection may be due to these participants 
having a worse health state overall and modelling their outcomes based on data from 
participants without such complications may not be justifiable. Additional assumptions 
about participants with missing data versus those with observed data may need to be 
postulated and justified, perhaps based on historical data. This is where the consideration of 
pandemic-related factors surrounding missingness, such as those mentioned in Table 4, is 
important. 
Pandemic-related missing data may need to be considered MNAR if missingness 
and study outcomes depend on COVID-19 related risk factors, treatment, and infection 
status but such data are not collected. The missingness mechanism may also be MNAR if it 
depends on unobserved study outcomes. In the context of the pandemic, it may arise when 
participants with milder disease or lower treatment response are more inclined to 
discontinue the study or treatment and if their outcomes and reasons for discontinuation are 
not documented before discontinuation. Analysis under MNAR requires additional 
unverifiable assumptions but may be avoided through collection of relevant data. Analysis 
of sensitivity to departures from MAR assumptions should be considered, for example, 
models assuming plausible MNAR mechanisms (see e.g., Carpenter et al., 2013; 
Mallinckrodt et al., 2020).  
Modifications to planned main analyses needed to handle pandemic-related missing 
data should be specified in the SAP prior to study unblinding. See Section 4.3.1 for a 
discussion of sensitivity analyses with respect to missing data. 
  
4.3. Considerations for Sensitivity and Supplementary Analysis 
Additional sensitivity and supplementary analyses will frequently be required to assess the 
impact of pandemic-related disruptions on the trial. For non-pandemic-related events and 
missing data, the originally planned sensitivity analyses should be performed, but simply 
applying the pre-planned sensitivity analyses to both pandemic and non-pandemic ICEs and 
missing data may be problematic for three reasons. First, the objective to estimate treatment 
effects in the absence of a COVID-19 pandemic may mandate different strategies for 
pandemic-related and unrelated events. Second, as discussed in Section 4.2.2, an MCAR or 
MAR assumption is frequently plausible for COVID-19-related events whereas this may 
not be the case for other missing data. Third, sensitivity analyses to missing data could 
become excessively conservative if the amount of pandemic-related missing data is large.  
While a relatively large proportion of missing data could normally be indicative of issues in 
trial design and execution leading to greater uncertainty in trial results, that premise is 
tenuous when an excess of missing data is attributed to the pandemic.   
Subgroup analyses for primary and secondary endpoints by enrolment or pandemic 
(see Section 4.3.3) period are recommended. If subgroup analyses are indicative of 
potential treatment effect heterogeneity, the potential for this to be rooted in regional 
differences should be considered. Issues of multiregional clinical trials as described in ICH 
(2017) may be magnified by the pandemic. In addition, dynamic period-dependent 
treatment effects could also be assessed in an exploratory fashion. For example, in models 
for longitudinal and time-to-event endpoints, one could include interaction terms between 
the treatment assignment and the exogenous time-varying covariate describing the patients’ 
dynamic status during follow-up. However, results from such analyses may be nontrivial to 
interpret and generalize.   
  
4.3.1. Sensitivity to Delayed Assessments and Missing Data 
More liberal visit time-windows may be appropriate for visits depending on the specific 
trial. Sensitivity analyses should assess the robustness of results to out-of-schedule visits by 
either including them or treating them as missing data.  
A tipping point analysis (Ratitch et al., 2013) may be used to assess how severe a 
departure from the missing data assumptions made by the main estimator must be to 
overturn the conclusions from the primary analysis. Tipping point adjustments may vary 
between the pandemic vs. non-pandemic missingness and by reason of missingness. For 
example, one could tip missing data due to pandemic-unrelated missing data but use 
standard MAR imputation for pandemic-related missing data. Historical data may be useful 
to put in context the plausibility of the assumptions and tipping point adjustments. 
When main analysis relies on imputation techniques, sensitivity analyses can be 
done by using an extended set of variables in the imputation algorithm.  
When dealing with missing data in a context of intercurrent events handled with the 
hypothetical strategy, one could vary the assumed probability that the participant would 
have adhered to treatment through the end of the study vs that they would have had other 
non-pandemic-related events and impute their outcomes accordingly.  
For binary responder analysis, it is not uncommon to treat participants who have 
missing assessments as non-responders when a proportion of such cases is very small. For 
pandemic-related delayed and missed assessments, especially those occurring in absence of 
ICEs, it may be preferable to use a hypothetical strategy based on a MAR assumption 
instead. However, anon-responder imputation for both non-pandemic and pandemic-related 
missing response assessments could be reported as a supplementary analysis. For time-to-
event endpoints, we recommend the usage of interval-censored methods to account for 
  
cases where the event of interest is known to have occurred during a period of missing or 
delayed visits but the time to event is not precisely known in sensitivity analyses (Bogaerts, 
Komarek, and Lesaffre, 2017).  
4.3.2. Sensitivity to Alternatives to Protocol-specified Study Data Collection 
Alternative measurements of endpoints may be necessary during the pandemic period. A 
careful study-specific assessment is necessary to judge whether these alternative 
measurements are exchangeable with standard protocol assessments. Ideally, 
exchangeability is established at the time of implementation based on information external 
to the trial.  If not, blinded data analyses can support this, e.g. comparisons of the 
distribution of alternative measurements to the original measurement. However, if the 
validity of the new instrument has not been established previously, it will be challenging to 
rigorously demonstrate equivalence using data from the trial alone.  
If exchangeability can be established or assumed, the main estimator could include 
data from both the original and the alternative data collection. The sensitivity analysis 
would then include data collected according to the original protocol only and treat other 
data as missing. If the validity of the exchangeability assumption is uncertain, the opposite 
approach can be taken. Modelling the interaction between treatment and assessment method 
can be undertaken as an alternate sensitivity analysis.  
4.3.3. Challenges in Understanding the General Pandemic Effect on Trial 
Outcomes 
 It will be important to understand the pandemic effect on trial outcomes. There are several 
schools of thought on how this could be done. Previous sections in this paper have 
described the need for collecting data describing how events such as missed visits and 
  
treatment interruptions can be attributed to the pandemic. These data are incorporated into 
definitions of pandemic-related ICEs and missing data, and the strategies for handling those 
in the analysis. Statistical analyses of trial data will then be properly adjusted for pandemic 
effects. In many ways this is the ideal approach as it incorporates what is known for each 
participant directly into the analysis, and in a way that is very well understood. This is a 
standard approach to adjusting statistical analysis for inevitable perturbations in clinical 
trials. This approach has the disadvantage of needing to collect detailed data on pandemic-
relatedness, which may not be feasible in some circumstances.  
Another approach involves the use of pandemic time periods defined external to the 
trial database (e.g., to define pre-/during/post-pandemic phases as described in 
EMA/CHMP 2020b). This approach requires the accurate and precise definition of 
pandemic periods.  This is simpler to apply in single-country studies where the impact of 
the pandemic and local containment measures may be relatively homogeneous across 
participants. However, even for a single country, the pandemic may evolve in a gradual 
fashion, complicating the definition of pandemic start and stop dates, and the impact of the 
pandemic on study participants will likely not be homogenous. Moreover, there may be 
several waves of infection outbreaks. The definition could prove even more challenging to 
implement in global trials because the start and stop dates of these periods and the impact 
of the pandemic on study participants may well vary by region. In practice, a standardized 
and pragmatic definition based on regionally reported numbers of COVID-19 cases and 
deaths over time and/or start date and stop dates of local containment measures will likely 
be required. Once pandemic periods have been defined, time-varying indicator variables for 
visits occurring during different pandemic periods could be incorporated as appropriate in 
statistical models or in ICE definitions, as discussed previously. When this approach is 
  
used, the rationale for defining the pandemic start and stop dates should be documented.  
The situation is evolving rapidly and at this is point, it is not possible to provide definitive 
recommendation on the definition, implementation, and interpretation of these pandemic 
periods. 
In a third approach to generally assessing pandemic effects, each participant in the 
trial could be categorized according to the extent of pandemic impact on their treatment and 
assessments collected in the study database (details of protocol deviation, ICEs, missing 
assessments, pandemic-related reasons for discontinuation etc.). For trials with a fixed 
follow-up duration and minimal loss to follow-up, the categorization could be integrated in 
standard analyses, for example in defining subgroups for standard subgroup analysis. 
There is insufficient evidence currently to favour a single approach to this issue. 
Sponsors are preparing to do at least the first two approaches, as these have been the 
subject of regulatory guidance. Until we see how they play out and how the pandemic 
evolves, etc., it’s sensible to consider multiple methods of summarizing pandemic effects.  
4.4. Considerations for Safety Analyses 
Standard safety summaries will include all AEs as usual. However, additional separate 
analyses may be needed for events associated with COVID-19 infections and unassociated 
events, respectively, to fully understand the safety profile. The determination whether AEs 
and, particularly, deaths are COVID-19 related should be made during trial monitoring 
before data unblinding to avoid bias.  
In many situations, safety reporting will remain unchanged. However, disruptions 
due to the COVID-19 pandemic may lead to increases in treatment interruptions, 
discontinuations and study withdrawals as well as the occurrence of COVID-19 infections 
  
and deaths. Hence, the estimands framework outlined in Section 3 could also be useful for 
safety analyses and we refer to (Unkel et al, 2019) for a general discussion of estimands as 
well as time-to-event and competing risks analyses for safety. Trials that require physical 
visits to adequately assess safety of the intervention will need to have maintained a 
schedule of physical visits to satisfy the requirement. Generally addressing the potential for 
bias in collection of AE data is beyond the scope of this paper. Exposure considering the 
compliance rate- or follow-up-adjusted analyses could be done, e.g., comparing the 
adjusted rates before and during the pandemic or with historical data. We don’t have other 
methodological recommendations at this time, and more research is needed. 
5. Study-Level Issues and Mitigations 
The cumulative impact of missing data and revised statistical models discussed in the 
previous sections contribute to an overall study-level impact. The cumulative effect could 
alter the likelihood of meeting trial objectives, or even the interpretability of the trial 
results. 
5.1. Assessing Impact of Missing Data and Study Drug Interruptions / 
Discontinuations 
Sponsors should assess potential impact of missing data on several aspects and it may be 
important to reach agreement with regulatory agencies on some of these questions: 
 Feasibility of planned estimation methods given the data expected to be available; 
 Potential for bias in treatment effect estimation if there are important differences in 
missingness patterns across treatment arms; 
 Study power for the primary and key secondary objectives; 
 Interpretability of study findings; 
  
 Adequacy of safety database due to potential reduction in total drug exposure time 
and potential for underreporting of AEs; 
 Adequacy of regional evidence required for regulatory submissions. 
5.2. Power and Probability of Success 
As discussed in the previous sections, COVID-19 related factors impact trial data in many 
ways with consequences for power of the study, probability of success, sample size or other 
aspects of the trial design.  
Quantifying the potential effects of the various pandemic factors on trial results can 
be done through clinical trial simulations. The simulation models will depend on the factors 
used in the original trial design, and incorporate adjustments to estimands, missing data 
handling and analysis methods as discussed in Sections 3 and 4. To maintain trial integrity, 
the simulations should be informed only by blinded data from the study and the assumed 
values for the design parameters from external sources. Variability and treatment effect 
estimates may be modified from their original values used in trial design. Trial properties 
such as power and probability of success can be updated accordingly. Sample size 
adjustment can be considered based on the simulation outcomes, or more extensive 
modifications of the trial design also may be considered such as change in the primary 
endpoint, analysis method, or addition of interim analysis with associated adaptation (Posch 
and Proschan 2012; Kieser and Friede 2003; Muller and Schaefer 2004). Such changes are 
challenging, and should be discussed with regulatory agencies, but can be considered if trial 
integrity is maintained. 
For some trials, it may not be feasible to increase sample size and the trial will fall 
short of enrollment target. Given the extraordinary circumstances, we advocate more 
  
flexibility to consider methods for quantifying evidence across multiple trials and sources, 
including use of historical control arm data and real-world data, although sources and 
methodology for selection of such data would need to be planned and agreed with 
regulatory agencies in advance. If the observed treatment effect after data unblinding is 
meaningful but does not meet the statistical criterion due to COVID-19 effects, the sponsor 
can evaluate whether the study results will be acceptable for registration on the basis of the 
accumulated evidence from the program; alternatively, whether the trial results could be 
used to define the inferential prior for a smaller follow up trial (Viele et al 2014).   
5.3. Considerations for the DMC and Interim Analyses 
For a trial with a DMC, the sponsor should ensure that the DMC is well-informed of all 
measures taken to protect participant safety and to address operational issues. Known or 
potential shortcomings of the data should be communicated. The timing of the regular pre-
planned safety interim analyses may need to be re-assessed. In addition, revised or 
additional data presentations may be needed. In some circumstances of interim analysis 
discussed in this section, a DMC may need to be established if not already in existence. 
There could also be circumstances related to participant safety where there may be a need 
to urgently review unblinded data, and establishing an internal DMC that is appropriately 
firewalled from the rest of the study team is recommended (e.g., studies without an existing 
DMC where it could take many months to organize an external DMC).  
Efficacy interim analyses should be conducted as planned with information level 
(e.g., number of participants with primary endpoint or specific information fraction) as 
described in the protocol, which may cause a delay in the expected timeline. Intermediate 
unplanned efficacy or futility interim analyses are generally discouraged unless there are 
  
safety and ethical considerations. However, if it is not feasible to reach the planned 
information level, altering the plan for interim analysis would need to be considered, for 
example with timing based on calendar time. In cases with strong scientific rationale for an 
unplanned interim analysis, the DMC should be informed and consulted on the time and 
logistics of the analysis. If an estimand, planned analysis methods, and/or decision rules 
have been changed to address pandemic-related disruptions and missing data, these changes 
should be communicated to the DMC and documented in the DMC charter. 
We do not generally advocate utilizing a DMC for operational risk assessment / 
mitigation process, to prevent influence of unblinded data on trial conduct decisions 
(EMA/CHMP 2005, FDA 2006). If the sponsor decides to involve the DMC, details should 
be clearly defined and documented in the DMC charter, including additional 
responsibilities of DMC members and measures to prevent introduction of bias.  
6. Conclusions 
As we have discussed, the COVID-19 outbreak continues to have major impact on planned 
and ongoing clinical trials. The effects on trial data have multiple implications. In many 
cases these may go beyond the individual clinical trial and will need to be considered when 
such results are included with other trial results, such as an Integrated Summary of Efficacy 
or Safety. Our goal was to describe the nature of the statistical issues arising from COVID-
19 potential impact on ongoing clinical trials and make general recommendations for 
solutions to address the issues.  
The following are the most important findings and recommendations: 
 Risk assessment, mitigation measures, and all changes to study conduct, data 
collection, and analysis must be documented in Statistical Analysis Plans and 
  
Clinical Study Reports as appropriate. Some changes may necessitate protocol 
amendments and consultation with regulatory agencies (FDA 2020, EMA 2020a, 
2020b). 
 Implications of the operational mitigations for the statistical analysis of the trial data 
should be considered before implementing those mitigations, especially for key 
efficacy and safety endpoints.  Validity and exchangeability of alternate methods of 
data collection require careful consideration. 
 The estimand framework, comprised of five key attributes, provides a pathway for 
assessing the impact of the pandemic on key study objectives in a systematic and 
structured manner and may be useful regardless of whether estimands are formally 
defined in the study protocol. 
 As much as possible, we recommend that original objectives of the trial be 
maintained; but some impact to planned estimands may be unavoidable. Pandemic-
related intercurrent events will likely need to be defined to properly and rigorously 
account for unexpected pandemic effects. 
 Planned efficacy and safety analyses should be reviewed carefully for changes 
needed to ensure that the estimators and missing data strategies align with updated 
estimands. Additional sensitivity and supportive analyses will be needed to fully 
describe the impact of the pandemic-related disruptions. 
 Sponsors should make every effort to minimize missing data without compromising 
safety of participants and study personnel and without placing undue burden on the 
healthcare system. Priority should be on the assessments which determine the 
  
primary endpoint, important safety endpoints, followed by the key secondary 
efficacy endpoints. 
 Most data that are missing due to pandemic reasons may be argued to be MCAR or 
MAR, especially if missingness is due to structural reasons, but additional 
considerations may apply, especially for certain diseases and participant-specific 
missingness. 
 Sponsors should carry out rigorous and systematic risk assessment concerning trial 
and data integrity and update it regularly. The ability of trials to meet their 
objectives should be assessed quantitatively, taking account of the impacts on trial 
estimands, missing data and missing data handling, and needed modifications to 
analysis methods. 
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